^
Association details:
| Biomarker: | RB1 expression |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma
Excerpt:
The trial was stopped early secondary to futility, with 95% (18 of 19) evaluable patients progressing within 6 months of intiating treatment. Median PFS was 5.14 weeks (range 5 days – 142 weeks) for all evaluable patients. Median OS was 15.4 weeks...palbociclib monotherapy was not an effective treatment for recurrent glioblastoma.
DOI:
10.1007/s11060-018-2977-3
Trial ID:
